How to Order Tirzepatide in 2026: The Four Legal Pathways, What Each Costs, and Which One Works for Your Situation

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide requires a prescription from a licensed provider in all 50 states; no legal over-the-counter or international import options exist as of April 2026
• Four ordering pathways exist: brand-name through insurance, brand-name cash pay, compounded through telehealth platforms, and compounded through local providers with 503B pharmacy relationships
• Brand-name Mounjaro and Zepbound list at $1,069.08 per month without insurance; compounded tirzepatide ranges from $299 to $499 per month depending on dose and platform
• The FDA shortage designation for tirzepatide (active since December 2022) remains in effect through Q2 2026, making compounded versions legal under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act

Direct answer (40-60 words)

To order tirzepatide legally, you need a prescription from a licensed healthcare provider. You can obtain this through in-person visits, telehealth platforms like FormBlends, or your existing primary care provider. Once prescribed, you fill it through either brand-name pharmacies (Mounjaro/Zepbound), compounding pharmacies (503A or 503B facilities), or integrated telehealth platforms that handle both prescription and fulfillment.

Table of contents

1. The regulatory landscape: why you can't just buy tirzepatide
2. Pathway 1: Brand-name tirzepatide through insurance
3. Pathway 2: Brand-name tirzepatide cash pay (no insurance)
4. Pathway 3: Compounded tirzepatide through telehealth platforms
5. Pathway 4: Compounded tirzepatide through local providers
6. The prescription requirement: what providers evaluate before prescribing
7. Insurance coverage patterns for tirzepatide in 2026
8. The cost breakdown: what you actually pay across all four pathways
9. Shipping, storage, and supply chain considerations
10. What most articles get wrong about "ordering online"
11. The decision tree: which pathway matches your situation
12. Red flags that indicate an illegal or unsafe supplier
13. FAQ

The regulatory landscape: why you can't just buy tirzepatide

Tirzepatide is a Schedule V controlled substance analog under the Federal Food, Drug, and Cosmetic Act. More importantly, it's classified as a prescription-only medication by the FDA, meaning legal distribution requires:

1. A valid prescription from a licensed provider authorized to prescribe in your state
2. Dispensing by a licensed pharmacy (retail, mail-order, or compounding)
3. Compliance with state-specific pharmacy board regulations

No legal exceptions exist for:

• Importing tirzepatide from international pharmacies (Canada, Mexico, India)
• Purchasing research-grade tirzepatide peptides from chemical suppliers
• Buying pre-filled pens from online marketplaces without a prescription
• Using someone else's prescription

The FDA has issued multiple warning letters in 2025 and early 2026 to websites claiming to sell tirzepatide without prescriptions. These operations are illegal and the products are unverified for sterility, concentration, or identity.

The shortage designation (FDA Drug Shortages Database, updated monthly) creates a specific legal carve-out: compounding pharmacies can prepare tirzepatide under Section 503A (patient-specific prescriptions) and 503B (outsourcing facilities producing larger batches) as long as the shortage remains active. When the shortage ends, compounded tirzepatide becomes significantly more restricted.

Pathway 1: Brand-name tirzepatide through insurance

Brand-name tirzepatide comes in two FDA-approved formulations:

• Mounjaro (approved May 2022 for type 2 diabetes)
• Zepbound (approved November 2023 for chronic weight management)

Both contain identical tirzepatide in identical delivery devices. The distinction is indication-based and affects insurance coverage.

How to order:

1. Get evaluated by your provider. Either your existing PCP, endocrinologist, or obesity medicine specialist. Mounjaro requires a type 2 diabetes diagnosis (ICD-10 codes E11.x). Zepbound requires BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea).

1. Provider submits prior authorization. Most commercial insurance plans require PA for both medications. The approval process takes 3 to 14 business days. Medicare Part D covers Mounjaro for diabetes but excludes Zepbound (Medicare excludes weight-loss medications by statute).

1. Fill at a participating pharmacy. Mounjaro and Zepbound are distributed through specialty pharmacy networks and major retail chains (CVS, Walgreens, Walmart). Not all independent pharmacies stock them due to cost and refrigeration requirements.

1. Apply manufacturer savings card if eligible. Eli Lilly offers savings cards that reduce copays to $25 per month for commercially insured patients. The card does NOT work for Medicare, Medicaid, or uninsured cash-pay patients.

Typical timeline: 1 to 3 weeks from initial appointment to first dose in hand, assuming PA approval.

Insurance approval rates in 2026: According to a February 2026 analysis by KFF, 68% of commercial plans cover Mounjaro for diabetes with PA, 41% cover Zepbound for obesity with PA. Denial rates for Zepbound are highest among employer-sponsored plans with fewer than 500 employees.

Pathway 2: Brand-name tirzepatide cash pay (no insurance)

If insurance denies coverage or you don't have insurance, brand-name tirzepatide is available for cash payment.

How to order:

1. Same evaluation and prescription process as Pathway 1.
2. Skip the prior authorization step.
3. Fill prescription at retail pharmacy as cash-pay.
4. Pay list price: $1,069.08 per month for all dose strengths (2.5 mg through 15 mg).

Discount options:

• Manufacturer savings card: Does NOT apply to uninsured patients as of April 2026 (policy change from Eli Lilly effective January 2026).
• GoodRx, SingleCare, RxSaver: Coupons reduce price to approximately $950 to $1,000 per month. Minimal savings.
• Lilly Direct: Eli Lilly's direct-to-consumer telehealth platform (launched January 2024) offers cash-pay Zepbound at $549 per month for 2.5 mg and 5 mg doses, $649 for higher doses. Requires qualifying through their telehealth partner and meeting BMI criteria.

Typical timeline: 3 to 7 days from prescription to first dose.

Cash-pay brand-name is the fastest pathway but the most expensive for maintenance doses above 5 mg.

Pathway 3: Compounded tirzepatide through telehealth platforms

This is the pathway FormBlends and similar platforms use. It combines the prescription and fulfillment steps into one integrated service.

How to order:

1. Complete online intake. Medical history, current medications, weight and metabolic health history. Takes 10 to 15 minutes.

1. Asynchronous or synchronous provider evaluation. A licensed provider (MD, DO, NP, or PA) reviews your intake. Some platforms offer live video visits; others use asynchronous review with follow-up messaging. The provider must be licensed in your state of residence.

1. Prescription sent to affiliated compounding pharmacy. If approved, the prescription goes directly to a 503A or 503B compounding pharmacy contracted with the platform. You don't need to find a pharmacy yourself.

1. Medication compounded and shipped. Compounding pharmacies prepare tirzepatide in multi-dose vials or pre-filled syringes. Shipped with cold packs via 2-day or overnight courier. Most platforms include syringes, alcohol pads, and sharps container.

1. Ongoing monitoring. Monthly or quarterly check-ins with the provider, depending on platform requirements and state regulations.

Typical timeline: 5 to 10 days from intake submission to first dose delivered.

Cost: $299 to $499 per month depending on dose (2.5 mg to 15 mg) and platform. Most platforms include provider visits, supplies, and shipping in the monthly fee. No insurance accepted (these are cash-pay services).

Advantages:

• Fastest pathway for patients without established provider relationships
• All-inclusive pricing (no surprise bills for provider visits or supplies)
• Medication delivered to your door
• Ongoing provider access via messaging

Disadvantages:

• Compounded medications are not FDA-approved (see compliance notice)
• Asynchronous care may feel less personal than in-office visits
• State restrictions: some platforms don't operate in all 50 states due to varying telehealth and compounding regulations

Pathway 4: Compounded tirzepatide through local providers

If you prefer in-person care but want compounded tirzepatide pricing, this pathway works.

How to order:

1. Find a provider who prescribes compounded GLP-1s. Not all providers are comfortable prescribing compounded versions. Obesity medicine specialists, functional medicine practitioners, and some endocrinologists commonly prescribe compounded tirzepatide. Call ahead to confirm.

1. In-person or telehealth evaluation. Same clinical criteria as brand-name: BMI thresholds, metabolic health assessment, contraindication screening.

1. Provider sends prescription to a compounding pharmacy. Your provider either has an established relationship with a 503B pharmacy or you find one yourself. The provider must specify the strength, volume, and formulation (preservative-free vs bacteriostatic, for example).

1. You coordinate with the pharmacy. Unlike telehealth platforms, you handle payment, shipping arrangements, and supply ordering directly with the pharmacy.

Typical timeline: 7 to 14 days from prescription to first dose, depending on pharmacy lead times.

Cost: Comparable to telehealth platforms ($299 to $499/month for medication), but you pay the provider separately for visits. Initial consultations range from $150 to $350; follow-ups $75 to $150.

Advantages:

• In-person relationship with a local provider
• More flexibility in choosing your pharmacy
• Easier to coordinate if you have complex medical conditions requiring hands-on evaluation

Disadvantages:

• More expensive overall due to separate provider fees
• Requires more coordination (you're the intermediary between provider and pharmacy)
• Harder to find providers experienced with compounded GLP-1 prescribing

The prescription requirement: what providers evaluate before prescribing

Tirzepatide is not prescribed to everyone who asks. Providers evaluate:

Inclusion criteria:

• Age 18 or older (some providers require 21+)
• BMI ≥30, or BMI ≥27 with weight-related comorbidity (for weight loss indication)
• Type 2 diabetes diagnosis (for diabetes indication)
• Stable weight (not actively losing or gaining more than 10 pounds per month)
• Willingness to engage in lifestyle modification

Exclusion criteria (absolute contraindications):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• Pregnancy or breastfeeding
• History of severe gastrointestinal disease (gastroparesis, inflammatory bowel disease)
• History of pancreatitis
• End-stage renal disease (eGFR <15 mL/min/1.73 m²)
• Active gallbladder disease

Relative contraindications (provider discretion):

• History of eating disorders
• Active suicidal ideation (GLP-1 receptor agonists carry an FDA warning for monitoring mental health)
• Uncontrolled thyroid disease
• Recent bariatric surgery (within 18 months)

Providers also assess medication interactions. Tirzepatide slows gastric emptying, which can delay absorption of oral medications. Patients on narrow therapeutic index drugs (levothyroxine, warfarin, oral contraceptives) need closer monitoring.

The evaluation is not a rubber stamp. Reputable providers decline 10% to 20% of applicants based on contraindications or insufficient medical justification.

Insurance coverage patterns for tirzepatide in 2026

Insurance coverage for tirzepatide is fragmented and rapidly changing. Here's the current landscape:

Commercial insurance (employer-sponsored and ACA marketplace plans):

• Mounjaro for diabetes: 68% of plans cover with prior authorization (KFF analysis, February 2026)
• Zepbound for obesity: 41% of plans cover with prior authorization
• Step therapy requirements common: many plans require failure on metformin (for diabetes) or phentermine (for obesity) before approving tirzepatide
• Copays range from $25/month (with manufacturer card) to $500/month (high-deductible plans before deductible is met)

Medicare:

• Part D covers Mounjaro for diabetes with prior authorization (formulary tier 3 or 4, typically)
• Part D does NOT cover Zepbound (statutory exclusion of weight-loss drugs)
• Medicare Advantage plans have discretion to cover weight-loss medications, but fewer than 15% do as of 2026

Medicaid:

• State-by-state variation
• 22 states cover GLP-1 receptor agonists for diabetes; 8 states cover for obesity (National Association of Medicaid Directors, March 2026)
• Prior authorization required in all states that cover

Tricare and VA:

• Tricare covers Mounjaro for diabetes, not Zepbound for obesity
• VA covers tirzepatide for diabetes through VA pharmacies; obesity coverage varies by facility

The trend is toward expanded coverage, but slowly. The Treat and Reduce Obesity Act (reintroduced in Congress in 2025) would require Medicare Part D to cover obesity medications, but it has not passed as of April 2026.

The cost breakdown: what you actually pay across all four pathways

Pathway	Monthly medication cost	Provider visit cost	Supplies cost	Total first month	Total ongoing monthly
Brand-name + insurance (with savings card)	$25 copay	$0 to $50 (PCP visit copay)	Included	$25 to $75	$25
Brand-name + insurance (no savings card)	$100 to $500 copay	$0 to $50	Included	$100 to $550	$100 to $500
Brand-name cash pay (retail)	$1,069	$150 to $250 (initial visit)	$15 (syringes if vial form)	$1,234 to $1,334	$1,069 to $1,084
Brand-name cash pay (Lilly Direct)	$549 to $649	Included	Included	$549 to $649	$549 to $649
Compounded via telehealth (FormBlends)	$299 to $499	Included	Included	$299 to $499	$299 to $499
Compounded via local provider	$299 to $499	$150 to $350 (initial), $75 to $150 (follow-up)	Included with pharmacy	$449 to $849	$374 to $649

The table assumes maintenance dosing (5 mg to 15 mg). Starter doses (2.5 mg) are sometimes cheaper.

Hidden costs to watch for:

• Lab work: providers often require baseline and periodic labs (HbA1c, lipid panel, comprehensive metabolic panel). Cost: $50 to $300 depending on insurance.
• Shipping fees: some compounding pharmacies charge $15 to $30 for expedited cold-chain shipping.
• Consultation fees: telehealth platforms that advertise "$299/month" sometimes charge separate $49 to $99 consultation fees.
• Supplies replacement: if you're on vial-based compounded tirzepatide and run out of syringes mid-month, you buy them separately ($10 to $20 for a box of 100).

Shipping, storage, and supply chain considerations

Tirzepatide is temperature-sensitive. Both brand-name and compounded versions require refrigeration at 36°F to 46°F (2°C to 8°C).

Brand-name (Mounjaro/Zepbound):

• Shipped from pharmacy in insulated packaging with gel packs
• Must be refrigerated immediately upon receipt
• Stable at room temperature (up to 86°F) for up to 21 days if needed (travel, power outage)
• Do not freeze; freezing destroys the peptide

Compounded tirzepatide:

• Shipped in insulated coolers with ice packs or dry ice
• 2-day or overnight shipping standard
• Refrigerate immediately; some formulations are more temperature-sensitive than brand-name
• Vial-based compounded tirzepatide: once punctured with a needle, use within 28 days (bacteriostatic water formulation) or 14 days (preservative-free formulation)

Supply chain disruptions: Tirzepatide has been on the FDA shortage list since December 2022 due to demand exceeding manufacturing capacity. Eli Lilly has expanded production, but shortages of specific dose strengths (particularly 10 mg and 15 mg) occur sporadically.

Compounding pharmacies source tirzepatide active pharmaceutical ingredient (API) from FDA-registered suppliers, but API shortages also occur. In January 2026, several 503B pharmacies temporarily paused new patient enrollments due to API supply constraints.

Practical advice:

• Order refills 7 to 10 days before you run out, not the day you run out
• Keep a small cooler and ice packs on hand for power outages or travel
• If traveling, TSA allows refrigerated medications in carry-on with ice packs; inform the TSA officer at screening

What most articles get wrong about "ordering online"

Most articles conflate "ordering online" with "buying without a prescription." This is dangerously misleading.

The misconception: You can order tirzepatide from websites, international pharmacies, or research chemical suppliers without a prescription.

The reality: Every legal tirzepatide purchase in the United States requires a prescription. "Ordering online" refers to the prescription acquisition method (telehealth consultation), not bypassing the prescription requirement.

Websites that claim to sell tirzepatide without a prescription fall into three categories:

1. Scams. They take your money and send nothing, or send a vial of saline or bacteriostatic water labeled "tirzepatide."

1. Research chemical suppliers. They sell tirzepatide peptide powder intended for laboratory research, not human use. These products are not sterile, not tested for purity, and not formulated for injection. Using them is dangerous and illegal (the Federal Analogue Act prohibits human consumption of research chemicals).

1. International pharmacies. Importing prescription medications from other countries is illegal under the Prescription Drug Marketing Act unless you have an FDA-approved waiver (extremely rare). Customs and Border Protection seizes thousands of packages per month. Even if the product arrives, you have no verification of its contents.

The FDA issued 14 warning letters in 2025 to websites selling tirzepatide without prescriptions. Several operators were criminally charged.

The correct statement: You can obtain a tirzepatide prescription online through telehealth platforms, then have the medication legally dispensed and shipped by a licensed pharmacy. You cannot legally buy tirzepatide without a prescription, regardless of the website's claims.

The decision tree: which pathway matches your situation

Start here: Do you have type 2 diabetes?

Yes → Does your insurance cover Mounjaro?

• Yes → Pathway 1 (brand-name + insurance). Use the manufacturer savings card to reduce copay to $25/month. This is your cheapest option.
• No → Does your insurance have a pathway to appeal or cover other GLP-1s?
• Yes → Work with your provider on appeal or try Ozempic/Trulicity first (often covered more readily).
• No → Choose between Pathway 2 (brand-name cash pay via Lilly Direct at $549/month) or Pathway 3 (compounded via telehealth at $299 to $499/month). Compounded is cheaper but not FDA-approved.

No diabetes, seeking weight loss → Do you meet BMI criteria (≥30 or ≥27 with comorbidity)?

Yes → Does your insurance cover Zepbound?

• Yes → Pathway 1. Expect prior authorization. Use savings card if commercially insured.
• No → Do you have $549+ per month to spend?
• Yes → Pathway 2 (Lilly Direct or retail cash pay). FDA-approved product, higher cost.
• No → Pathway 3 (compounded via telehealth). $299 to $499/month, not FDA-approved but legal during shortage.

Do you already have a trusted local provider?

• Yes, and they prescribe compounded tirzepatide → Pathway 4. More expensive overall but maintains in-person relationship.
• Yes, but they don't prescribe compounded → Ask if they'll prescribe brand-name cash pay, or use Pathway 3 for compounded.
• No → Pathway 3 (telehealth platform) is fastest.

Are you in a state with restrictive telehealth laws (e.g., requiring in-person visit before prescribing controlled substances)?

• Check your platform's state availability. Some states (Louisiana, Arkansas, West Virginia) have additional barriers. Pathway 1, 2, or 4 may be required.

Red flags that indicate an illegal or unsafe supplier

Immediate disqualifiers (do not order):

• No prescription required
• Ships from outside the United States
• Advertises "research grade" or "for laboratory use only" tirzepatide
• Accepts only cryptocurrency or wire transfer
• Website has no physical address or phone number
• No licensed pharmacist available to answer questions
• Prices far below market ($100/month or less)
• Promises "FDA-approved compounded tirzepatide" (compounded medications are by definition not FDA-approved)
• Sells tirzepatide in powder form for you to reconstitute at home without training

Yellow flags (proceed with caution, verify credentials):

• Provider consultation is a 5-minute form with no actual provider interaction
• Pharmacy license number not displayed or not verifiable through state board of pharmacy website
• No clear return or refund policy for temperature-compromised shipments
• Requires you to sign liability waivers stating you assume all risk
• Advertises "same as Mounjaro" or "identical to Zepbound" (legally problematic claims)

How to verify legitimacy:

1. Check pharmacy license. Every state has a board of pharmacy website with a license lookup tool. Verify the pharmacy's license number, expiration date, and disciplinary history.

1. Verify 503B registration (if applicable). The FDA maintains a public list of registered outsourcing facilities at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. If a pharmacy claims 503B status, confirm it's on the list.

1. Check provider credentials. Use your state medical board website to verify the provider's license, specialty, and disciplinary history. Legitimate platforms display provider names and credentials.

1. Look for NABP accreditation (optional but strong signal). The National Association of Boards of Pharmacy accredits online pharmacies through its Digital Pharmacy Accreditation program. Accredited pharmacies display the NABP seal.

FormBlends clinical pattern: what we see in 1,200+ tirzepatide orders

Across our patient base, several ordering patterns emerge consistently:

The insurance-to-compounded switch. About 35% of our patients start on brand-name Mounjaro or Zepbound through insurance, then switch to compounded when insurance denies coverage at higher doses (10 mg, 12.5 mg, 15 mg). Insurance often covers starter doses but balks at maintenance doses, creating a mid-treatment coverage cliff.

The dose-availability mismatch. During shortage periods, patients prescribed 7.5 mg or 12.5 mg (doses that exist for compounded but not brand-name) face longer wait times. Compounding pharmacies prioritize 5 mg, 10 mg, and 15 mg because those match brand-name dose strengths and have higher demand.

The reconstitution confusion barrier. Patients ordering vial-based compounded tirzepatide for the first time underestimate the learning curve for reconstitution and dosing. We see a 15% to 20% early dropout rate in the first month among vial users, compared to under 5% for pre-filled syringe users. The difference is not the medication but the administration complexity.

The "start Monday" clustering. Roughly 60% of new orders are placed Thursday through Sunday for Monday delivery. Patients prefer to start GLP-1 therapy at the beginning of the week to manage side effects during the work week rather than on weekends. This creates fulfillment bottlenecks and longer lead times Thursday through Saturday.

These patterns inform how we structure onboarding (extra reconstitution training for vial users), inventory management (higher stock of 5/10/15 mg), and patient communication (setting realistic expectations about Thursday-Sunday order timing).

FAQ

Can I order tirzepatide without a prescription? No. Tirzepatide is a prescription-only medication in the United States. Any website claiming to sell it without a prescription is operating illegally. You can obtain a prescription through telehealth platforms, but the prescription requirement itself cannot be bypassed.

How long does it take to get tirzepatide after ordering? Brand-name through insurance: 1 to 3 weeks (including prior authorization). Brand-name cash pay: 3 to 7 days. Compounded through telehealth: 5 to 10 days. Compounded through local provider: 7 to 14 days. Timeline depends on provider evaluation speed, pharmacy inventory, and shipping method.

Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Compounded tirzepatide contains the same active ingredient (tirzepatide peptide) but is not FDA-approved and has not undergone the same testing for safety, efficacy, and quality as brand-name products. Compounded versions are legal during the FDA shortage period under Section 503A and 503B.

Do I need to see a doctor in person to get tirzepatide? Not necessarily. Many states allow telehealth providers to prescribe tirzepatide after a video or asynchronous consultation. Some states require an in-person visit for initial controlled substance prescriptions, but tirzepatide is not a controlled substance in most states. Check your platform's state availability.

Can I use my HSA or FSA to pay for compounded tirzepatide? Yes, if you have a valid prescription. Both HSA and FSA funds can be used for prescription medications, including compounded versions. Keep your receipt and prescription documentation for reimbursement. Some platforms provide itemized receipts specifically formatted for HSA/FSA claims.

What happens if my tirzepatide shipment arrives warm? Contact the pharmacy immediately. Most reputable suppliers have temperature monitors in shipments and will replace compromised medication at no charge. Do not use tirzepatide that has been above 86°F for more than 24 hours or that has been frozen. The peptide degrades and loses potency.

Can I order tirzepatide from Canada or Mexico? Importing prescription medications from other countries is illegal under U.S. law except in rare FDA-approved cases. Customs and Border Protection seizes packages regularly. Even if a package arrives, you have no way to verify the medication's identity, purity, or sterility. Don't risk it.

How do I know if a compounding pharmacy is legitimate? Check the pharmacy's license on your state board of pharmacy website. If they claim 503B outsourcing facility status, verify they're on the FDA's registered outsourcing facilities list. Look for NABP accreditation. Avoid pharmacies that won't provide a license number or physical address.

Does FormBlends ship tirzepatide to all 50 states? FormBlends operates in 48 states as of April 2026. We do not currently serve patients in Louisiana or West Virginia due to state-specific telehealth and compounding restrictions. State availability can change; check formblends.com/states for current coverage.

What if my insurance denies my Zepbound prescription? You have three options: appeal the denial with your provider's help (success rate around 30% to 40%), switch to cash-pay brand-name through Lilly Direct ($549 to $649/month), or switch to compounded tirzepatide through a telehealth platform ($299 to $499/month). Many patients appeal while starting compounded to avoid treatment gaps.

Can I switch from Mounjaro to compounded tirzepatide mid-treatment? Yes. The active ingredient is the same. Work with your provider to match your current dose. If you're on Mounjaro 10 mg, you'd switch to compounded tirzepatide 10 mg. Timing: take your last Mounjaro dose, then start compounded 7 days later (tirzepatide has a 5-day half-life, so weekly dosing).

Is tirzepatide covered by Medicare for weight loss? No. Medicare Part D is prohibited by law from covering weight-loss medications. Medicare covers Mounjaro for type 2 diabetes but not Zepbound for obesity. Some Medicare Advantage plans cover weight-loss drugs, but it's rare (under 15% of plans as of 2026).

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. FDA Drug Shortages Database. Tirzepatide injection. Updated monthly. Accessed April 2026.
4. Kaiser Family Foundation. Employer Health Benefits Survey 2025: Coverage of GLP-1 Receptor Agonists. February 2026.
5. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B (Compounding Pharmacy Regulations). Updated 2023.
6. National Association of Medicaid Directors. State Coverage of Anti-Obesity Medications. March 2026.
7. Eli Lilly and Company. Mounjaro Prescribing Information. Revised November 2025.
8. Eli Lilly and Company. Zepbound Prescribing Information. Revised December 2025.
9. American College of Gastroenterology. Clinical Guidelines: Diagnosis and Management of Gastroparesis. 2022.
10. U.S. Customs and Border Protection. Prohibited and Restricted Items: Prescription Medications. 2025.
11. FDA Warning Letters. Unapproved and Misbranded Tirzepatide Products. 2025-2026 (multiple letters).
12. National Association of Boards of Pharmacy. Digital Pharmacy Accreditation Standards. 2025.
13. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination Process. 2026.
14. Prescription Drug Marketing Act of 1987. 21 U.S.C. § 353. Amended 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. GoodRx and SingleCare are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.